Correlation between SIRT1 expression and overall survival across various cancers: A meta-analysis

Abstract

Sirtuin 1 (SIRT1) plays a complex role in cancer, significantly influencing cancer prognosis. However, its true impact remains unclear, necessitating a comprehensive and unified analysis. This study investigates the prognostic value of SIRT1 expression across different cancers worldwide. Relevant studies were retrieved from Google Scholar, PubMed, and Web of Science. Only human studies exploring the prognostic role of SIRT1 in various cancers were included in the study. Data on patient demographics, SIRT1 expression levels, and overall survival (OS) rates were extracted, followed by subsequent analyses, including meta-regression for heterogeneity and Egger’s regression for publication bias. A total of 15 studies (pooled hazard ratio = 1.483 ± 0.2974 [95% CI: 0.900 - 2.065]), predominantly from Asia (n = 10), were selected for the meta-analysis. The analysis demonstrated a robust and consistent association between elevated SIRT1 expression and poorer OS across diverse variables (P < 0.001), with minimal heterogeneity (I2 = 0.0001). Subgroup analyses confirmed significant effects of SIRT1 on OS rates based on regions (Asia: P < 0.001; non-Asia: P < 0.001), study size (small: P = 0.001, medium: P = 0.002, and large cohorts: P = 0.021), and specific cancer types (ovarian: P = 0.041, lung: P = 0.025, and gastric cancer: P = 0.025). However, no significant impact was observed in breast (P = 0.136) and colorectal cancers (P = 0.221). Overall, SIRT1 demonstrates consistent prognostic significance across various cancers and populations. However, the assessment of its long-term prognostic effects remains elusive, highlighting the need for further mechanistic research to guide targeted interventions and precision medicine in cancer therapy.

Keywords

Sirtuin / Prognosis / Cancer / Precision medicine / Oncology research

Funding

None.

Conflict of interest

Umair Ali Khan Saddozai and Xin-Ying Ji are members of the Editorial Board of this journal but were not involved in the editorial and peer-review processes for this paper, either directly or indirectly. Separately, the other authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] Kumar A, Chauhan S. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem. 2016; 119:45-69. doi: 10.1016/j.ejmech.2016.04.063

[2] McBurney MW, Clark-Knowles KV, Caron AZ, Gray DA. SIRT1 is a highly networked protein that mediates the adaptation to chronic physiological stress. Genes Cancer. 2013; 4(3-4):125-134. doi: 10.1177/1947601912474893

[3] Luo J, Nikolaev AY, Imai SI, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell. 2001; 107(2):137-148. doi: 10.1016/s0092-8674(01)00524-4

[4] Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14(4):312-323. doi: 10.1016/j.ccr.2008.09.001

[5] Khawar MB, Sohail AM, Li W. SIRT1: A key player in male reproduction. Life. 2022; 12(2):318. doi: 10.3390/life12020318

[6] Khawar MB, Liu C, Gao F, et al. Sirt1 regulates testosterone biosynthesis in Leydig cells via modulating autophagy. Protein Cell. 2021; 12(1):67-75. doi: 10.1007/s13238-020-00771-1

[7] Wang XW, Jiang YH, Ye W, Shao CF, Xie JJ, Li X.SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis. Cancer Biol Ther. 2023; 24(1):2235770. doi: 10.1080/15384047.2023.2235770

[8] Carafa V, Altucci L, Nebbioso A. Dual tumor suppressor and tumor promoter action of sirtuins in determining malignant phenotype. Front Pharmacol. 2019;10:38. doi: 10.3389/fphar.2019.00038

[9] Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019; 20(13):3153. doi: 10.3390/ijms20133153

[10] Karbasforooshan H, Roohbakhsh A, Karimi G. SIRT1 and microRNAs: The role in breast, lung and prostate cancers. Exp Cell Res. 2018; 367(1):1-6. doi: 10.1016/j.yexcr.2018.03.023

[11] Shuang T, Wang M, Zhou Y, Shi C. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC). Med Oncol. 2015;32:260. doi: 10.1007/s12032-015-0706-8

[12] Noguchi A, Kikuchi K, Zheng H, et al. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. 2014; 3(6):1553-1561. doi: 10.1002/cam4.310

[13] Lee CW, Wong LL, Tse EY, et al. AMPK Promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res. 2012; 72(17):4394-4404. doi: 10.1158/0008-5472.CAN-12-0429

[14] Zhang H, Ma C, Peng M, Lv X, Xie X, Huang R. The prognostic implications of SIRTs expression in breast cancer: A systematic review and meta-analysis. Disc Oncol. 2022; 13(1):69. doi: 10.1007/s12672-022-00529-7

[15] Wang C, Yang W, Dong F, et al. The prognostic role of Sirt1 expression in solid malignancies: A meta-analysis. Oncotarget. 2017; 8(39):66343-66351. doi: 10.18632/oncotarget.18494

[16] Cao YW, Li YC, Wan GX, Du XM, Li F. Clinicopathological and prognostic role of SIRT1 in breast cancer patients: A meta-analysis. Int J Clin Exp Med. 2015; 8(1):616-624.

[17] Sun M, Du M, Gong X. Survival and clinicopathological significance of SIRT1 expression in cancers: A meta-analysis. Front Endocrinol. 2019;10:442007.

[18] Otsuka R, Sakata H, Murakami K, et al. SIRT1 expression is a promising prognostic biomarker in esophageal squamous cell carcinoma: A systematic review and meta-analysis. Cancer Diagn Prog. 2022; 2(2):126-133. doi: 10.21873/cdp.10086

[19] Zhang YL, Chen P, Guo Y, Zhang YJ. Clinical value of SIRT1 as a prognostic biomarker in esophageal squamous cell carcinoma, a systematic meta-analysis. Open Med. 2022; 17(1):527-535. doi: 10.1515/med-2022-0454

[20] Jung W, Hong KD, Jung WY, et al. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol. 2013; 47(4):332-339. doi: 10.4132/KoreanJPathol.2013.47.4.332

[21] Zhou J, Xu M, Le K, et al.SRC promotes tamoxifen resistance in breast cancer via up-regulating SIRT1. Onco Targets Ther. 2020; 13:4635-4647. doi: 10.2147/OTT.S245749

[22] Tan J, Liu Y, Maimaiti Y, et al. Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer. Onco Targets Ther. 2018; 11:2051-2061. doi: 10.2147/OTT.S162503

[23] Ryota O, Hiroki M, Keiko I, et al. Serum versus tissue SIRT1 as potentially valuable biomarkers in gastric cancer. Anticancer Res. 2023; 43(4):1485. doi: 10.21873/anticanres.16297

[24] Benard A, Goossens‐Beumer IJ, van Hoesel AQ, et al. Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer. Histopathology. 2015; 66(2):270-282. doi: 10.1111/his.12534

[25] Li C, Wang L, Zheng L, et al. SIRT1 expression is associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther. 2015; 8:977-984. doi: 10.2147/OTT.S82378

[26] Grbesa I, Pajares MJ, Martinez-Terroba E, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015; 10(4):e0124670. doi: 10.1371/journal.pone.0124670

[27] Zhang X, Chen S, Cheng M, Cao F, Cheng Y. The expression and correlation of SIRT1 and Phospho-SIRT1 in colorectal cancer. Int J Clin Exp Med. 2015; 8(1):809-817.

[28] Teramae M, Fukuda T, Wada T, et al. Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer. Mol Clin Oncol. 2015; 3(1):73-78. doi: 10.3892/mco.2014.427

[29] Qiu G, Li X, Wei C, et al. The prognostic role of SIRT1-autophagy axis in gastric cancer. Dis Markers. 2016; 2016(1): 6869415. doi: 10.1155/2016/6869415

[30] Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016; 7(31):49322. doi: 10.18632/oncotarget.10337

[31] Chung SY, Jung YY, Park IA, et al. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clin Exp Metastasis. 2016;33:179-185. doi: 10.1007/s10585-015-9767-5

[32] Jeh SU, Park JJ, Lee JS, et al. Differential expression of the sirtuin family in renal cell carcinoma: aspects of carcinogenesis and prognostic significance. Urol Oncol. 2017;35:675-e79. doi: 10.1016/j.urolonc.2017.08.016

[33] Mvunta DH, Miyamoto T, Asaka R, et al. Overexpression of SIRT1 is associated with poor outcomes in patients with ovarian carcinoma. Appl Immunohistochem Mol Morphol. 2017; 25(6):415-421. doi: 10.1097/PAI.0000000000000316

[34] Gharabaghi MA. Diagnostic investigation of BIRC 6 and SIRT 1 protein expression level as potential prognostic biomarkers in patients with non‐small cell lung cancer. Clin Respir J. 2018; 12(2):633-638. doi: 10.1111/crj.12572

[35] Tan Y, Li B, Peng F, Gong G, Li N. Integrative analysis of sirtuins and their prognostic significance in clear cell renal cell carcinoma. Front Oncol. 2020;10:218. doi: 10.3389/fonc.2020.00218

[36] Beyer S, Chen F, Meister S, et al. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. Histochem Cell Biol. 2020; 154:189-195. doi: 10.1007/s00418-020-01873-x

[37] Chen F. The Expression of Sirtuin1 and Its Role in Ovarian Cancer. Germany: Ludwig Maximilian University of Munich; 2022.

[38] Jiang B, Chen JH, Yuan WZ, et al. Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis. J Huazhong Univ Sci Technol. 2016; 36(2):278-284. doi: 10.1007/s11596-016-1580-0

[39] Wu S, Jiang J, Liu J, Wang X, Gan Y, Tang Y. Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer. Oncotarget. 2017; 8(37):62589-62599. doi: 10.18632/oncotarget.19880

[40] Ozcan O, Belli AK, Cetin ES, et al. Upregulation of SIRT1 gene in gastric adenocarcinoma. Turk J Gastroenterol. 2019; 30(4):326-330. doi: 10.5152/tjg.2019.18550

[41] Feng AN, Zhang LH, Fan XS, et al. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol. 2011; 19(6):743-750. doi: 10.1177/1066896911412181

[42] Jiang K, Lyu L, Shen Z, et al. Overexpression of SIRT1 is a poor prognostic factor for advanced colorectal cancer. Chin Med J. 2014; 127(11):2021-2024.

[43] Zhou Y, Cheng S, Chen S, Zhao Y. Prognostic and clinicopathological value of SIRT3 expression in various cancers: A systematic review and meta-analysis. Onco Targets Ther. 2018; 11:2157-2167. doi: 10.2147/OTT.S157836

[44] García-Martínez JM, Chocarro-Calvo A, Martínez-Useros J, et al. Vitamin D induces SIRT1 activation through K610 deacetylation in colon cancer. eLife. 2023;12:RP86913. doi: 10.7554/eLife.86913

[45] Wang TW, Chern E, Hsu CW, Tseng KC, Chao HM. SIRT1- Mediated expression of CD24 and epigenetic suppression of novel tumor suppressor miR-1185-1 increases colorectal cancer stemness. Cancer Res. 2020; 80(23):5257-5269. doi: 10.1158/0008-5472.CAN-19-3188

[46] Yu L, Dong L, Li H, et al. Ubiquitination-mediated degradation of SIRT1 by SMURF2 suppresses CRC cell proliferation and tumorigenesis. Oncogene. 2020; 39(22):4450-4464. doi: 10.1038/s41388-020-1298-0

[47] Lin EI, Tseng LH, Gocke CD, et al. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget. 2015; 6(39):42334-42344. doi: 10.18632/oncotarget.5997

[48] Dong W, Lu J, Li Y, et al. SIRT1: A novel regulator in colorectal cancer. Biomed Pharmacother. 2024;178:117176. doi: 10.1016/j.biopha.2024.117176

[49] Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep. 2022;10:goac035. doi: 10.1093/gastro/goac035

[50] Deng Y, Wang Y, Li L, Miao EA, Liu P. Post-translational modifications of proteins in cytosolic nucleic acid sensing signaling pathways. Front Immunol. 2022;13:898724. doi: 10.3389/fimmu.2022.898724

[51] Kang JA, Kim YJ, Jang KY, et al. SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity. Exp Mol Med. 2024; 56(3):656-673. doi: 10.1038/s12276-024-01194-2

[52] Morishita H, Otsuka R, Murakami K, et al. SIRT1 Promotes chemoradiotherapy resistance in esophageal squamous cell carcinoma. Oncology. 2024;102:960-968. doi: 10.1159/000540247